NA Artificial Intelligence (AI) in Drug Discovery Market - Industry Trends and Forecast to 2029
- Published Date: 2022-12-22
- Report ID: 143116
- Pages: 225
-
Format:
Short Description
North America Artificial Intelligence (AI) in Drug Discovery Market, By Application (Novel Drug Candidates, Drug Optimization and Repurposing Preclinical Testing and Approval, Drug Monitoring, Finding New Diseases Associated Targets and Pathways, Understanding Disease Mechanisms, Aggregating and Synthesizing Information, Formation & Qualification of Hypotheses, De Novo Drug Design, Finding Drug Targets of an Old Drug, and Others), Technology (Machine Learning, Deep Learning, Natural Language Processing, and Others), Drug Type (Small Molecule and Large Molecule), Offering (Software and Services.), Indication (Immuno-Oncology, Neurodegenerative Diseases, Cardiovascular Diseases, Metabolic Diseases, and Others), End Use (Contract Research Organizations (CROs), Pharmaceutical & Biotechnology Companies, Research Centers and Academic Institutes, and Others), Country (U.S., Canada, and Mexico) Industry Trends and Forecast to 2029
Market Definition
Artificial Intelligence (AI) has caught the attention and minds of medical technology practitioners in the past few years, as several companies and major research laboratories have worked to perfect these technologies for clinical use. The first commercialized demonstrations of how AI (also known as Deep Learning (DL), Machine Learning (ML), or Artificial Neural Networks (ANNs)) could assist clinicians are now available. These systems could lead to a paradigm shift in clinician workflow, increase productivity while simultaneously enhancing treatment and patient throughput. AI for drug discovery is a technology that uses machines to simulate human intelligence in order to solve complicated challenges in the drug development procedure. The adoption of AI solutions in the clinical trial process eliminates possible obstacles, reduces clinical trial cycle time, and increases the productivity and accuracy of the clinical trial process. Therefore, the adoption of these advanced AI solutions in drug discovery processes is gaining popularity amongst life science industry stakeholders. In the pharmaceutical sector, it aids in the discovery of novel compounds, therapeutic target identification, and the development of customized medications. AI platforms used for drug discovery can prove to be a feasible option for deriving insights into the discovery of drugs to treat and minimize the severity of various chronic diseases.
Market Segmentation
North America Artificial Intelligence (AI) in drug discovery market is categorized into six notable segments: application, technology, drug type, offering, indication, and end use.
On the basis of application, the market is segmented into novel drug candidates, drug optimization and repurposing preclinical testing and approval, drug monitoring, finding new diseases associated targets and pathways, understanding disease mechanisms, aggregating and synthesizing information, formation & qualification of hypotheses, de novo drug design, finding drug targets of an old drug, and others
On the basis of technology, the market is segmented into Machine Learning (ML), Deep Learning (DL), Natural Language Processing (NLP), and others
On the basis of drug type, the market is segmented into small molecule and large molecule
On the basis of offering, the market is segmented into software and services
On the basis of indication, the market is segmented into immuno-oncology, neurodegenerative diseases, cardiovascular diseases, metabolic diseases, and others
On the basis of end use, the market is segmented into pharmaceutical & biotechnology companies, Contract Research Organizations (CROs), research centers and academic institutes, and others
Market Players
The key market players operating in the North America Artificial Intelligence (AI) in drug discovery market are listed below:
NVIDIA Corporation
IBM Corp.
Atomwise Inc.
Microsoft
TABLE OF CONTENTS
1 INTRODUCTION 33
1.1 OBJECTIVES OF THE STUDY 33
1.2 MARKET DEFINITION 33
1.3 OVERVIEW OF NORTH AMERICA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET 33
1.4 CURRENCY AND PRICING 35
1.5 LIMITATIONS 35
1.6 MARKETS COVERED 36
2 MARKET SEGMENTATION 39
2.1 MARKETS COVERED 39
2.2 GEOGRAPHICAL SCOPE 40
2.3 YEARS CONSIDERED FOR THE STUDY 41
2.4 DBMR TRIPOD DATA VALIDATION MODEL 42
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 45
2.6 MULTIVARIATE MODELLING 46
2.7 MARKET APPLICATION COVERAGE GRID 47
2.8 SOURCE LIFELINE CURVE 48
2.9 DBMR MARKET POSITION GRID 49
2.10 VENDOR SHARE ANALYSIS 51
2.11 SECONDARY SOURCES 52
2.12 ASSUMPTIONS 52
3 EXECUTIVE SUMMARY 53
4 PREMIUM INSIGHT 56
4.1 PESTEL ANALYSIS 57
4.2 PORETSRS FIVE FORCES 58
5 MARKET OVERVIEW 59
5.1 DRIVERS 61
5.1.1 THE RISE IN INCIDENCE OF CHRONIC DISEASES PROPELS NEED FOR ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY 61
5.1.2 STRATEGIC COLLABORATIONS, PARTNERSHIPS, AND PRODUCTS LAUNCH 61
5.1.3 REDUCTION IN TOTAL TIME INVOLVED IN DRUG DISCOVERY PROCESS 62
5.1.4 ADVANCEMENT OF ARTIFICIAL INTELLIGENCE IN THE HEALTHCARE INDUSTRY 62
5.2 RESTRAINTS 63
5.2.1 HIGH COST ASSOCIATED WITH TECHNOLOGY AND TECHNICAL LIMITATIONS 63
5.2.2 DISADVANTAGES AND RISKS ASSOCIATED WITH AI IN DRUG DISCOVERY 63
5.2.3 LACK OF AVAILABLE QUALITY DATA 63
5.3 OPPORTUNITIES 64
5.3.1 RISE IN THE INVESTMENTS FOR R&D 64
5.3.2 RISING HEALTHCARE INFRASTRUCTURE 64
5.3.3 DEVELOPMENT OF NOVEL TOOLS 65
5.4 CHALLENGES 65
5.4.1 THE NORTH AMERICA SHORTAGE OF AI TALENT 65
5.4.2 ETHICAL, LEGAL, AND REGULATORY ISSUES FOR AI ADOPTION IN THE PHARMACEUTICAL SCIENCES 66
6 NORTH AMERICA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY OFFERING 67
6.1 OVERVIEW 68
6.2 SOFTWARE 71
6.2.1 INTEGRATED 72
6.2.2 STANDALONE 72
6.3 SERVICES 72
7 NORTH AMERICA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY TECHNOLOGY 74
7.1 OVERVIEW 75
7.2 MACHINE LEARNING (ML) 78
7.2.1 SUPERVISED LEARNING 79
7.2.2 UNSUPERVISED LEARNING 79
7.2.3 REINFORCEMENT LEARNING 79
7.3 DEEP LEARNING 79
7.4 NATURAL LANGUAGE PROCESSING (NLP) 80
7.5 OTHERS 81
8 NORTH AMERICA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET , BY DRUG TYPE 82
8.1 OVERVIEW 83
8.2 SMALL MOLECULE 86
8.3 LARGE MOLECULE 86
9 NORTH AMERICA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY APPLICATION 88
9.1 OVERVIEW 89
9.2 NOVEL DRUG CANDIDATES 92
9.2.1 PREDICT BIOACTIVITY OF SMALL MOLECULE 93
9.2.2 IDENTIFY BIOLOGICS TARGET 93
9.2.3 OTHERS 93
9.3 DRUG OPTIMISATION AND RE-PURPOSING PRE-CLINICAL TESTING AND APPROVAL 93
9.4 DRUG MONITORING 94
9.5 AGGREGATING AND SYNTHESIZING INFORMATION 95
9.6 DE NOVO DRUG DESIGN 95
9.7 FINDING DRUG TARGETS OF AN OLD DRUG 96
9.8 FORMATION & QUALIFICATION OF HYPOTHESES 97
9.9 UNDERSTANDING DISEASE MECHANISMS 98
9.10 FINDING NEW DISEASE-ASSOCIATED TARGETS AND PATHWAYS 98
9.11 OTHERS 99
10 NORTH AMERICA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY INDICATION 101
10.1 OVERVIEW 102
10.2 IMMUNE-ONCOLOGY 105
10.2.1 BREAST CANCER 106
10.2.2 LUNG CANCER 106
10.2.3 COLORECTAL CANCER 106
10.2.4 PROSTATE CANCER 106
10.2.5 PANCREATIC CANCER 106
10.2.6 BRAIN CANCER 106
10.2.7 LEUKEMIA 107
10.2.8 OTHERS 107
10.3 NEURODEGENERATIVE DISEASES 107
10.4 CARDIOVASCULAR DISEASES 108
10.5 METABOLIC DISEASES 108
10.6 OTHERS 109
11 NORTH AMERICA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET , BY END USE 110
11.1 OVERVIEW 111
11.2 CONTRACT RESEARCH ORGANIZATIONS 114
11.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 114
11.4 RESEARCH CENTERS AND ACADEMIC INSTITUTES 115
11.5 OTHERS 116
12 NORTH AMERICA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY REGION 117
12.1 NORTH AMERICA 118
12.1.1 U.S. 126
12.1.2 CANADA 130
12.1.3 MEXICO 134
13 NORTH AMERICA ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET: COMPANY LANDSCAPE 138
13.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 138
14 SWOT ANALYSIS 139
15 COMPANY PROFILES 140
15.1 NVIDIA CORPORATION 140
15.1.1 COMPANY SNAPSHOT 140
15.1.2 REVENUE ANALYSIS 140
15.1.3 COMPANY SHARE ANALYSIS 141
15.1.4 PRODUCT PORTFOLIO 141
15.1.5 RECENT DEVELOPMENTS 141
15.2 MICROSOFT 142
15.2.1 COMPANY SNAPSHOT 142
15.2.2 REVENUE ANALYSIS 142
15.2.3 COMPANY SHARE ANALYSIS 143
15.2.4 PRODUCT PORTFOLIO 143
15.2.5 RECENT DEVELOPMENT 143
15.3 IBM CORP 144
15.3.1 COMPANY SNAPSHOT 144
15.3.2 REVENUE ANALYSIS 144
15.3.3 COMPANY SHARE ANALYSIS 145
15.3.4 PRODUCT PORTFOLIO 145
15.3.5 RECENT DEVELOPMENT 145
15.4 SCHRDINGER, INC. 146
15.4.1 COMPANY SNAPSHOT 146
15.4.2 REVENUE ANALYSIS 146
15.4.3 COMPANY SHARE ANALYSIS 147
15.4.4 PRODUCT PORTFOLIO 147
15.4.5 RECENT DEVELOPMENTS 147
15.5 BERG LLC 149
15.5.1 COMPANY SNAPSHOT 149
15.5.2 COMPANY SHARE ANALYSIS 149
15.5.3 PRODUCT PORTFOLIO 149
15.5.4 RECENT DEVELOPMENTS 150
15.6 ARDIGEN 151
15.6.1 COMPANY SNAPSHOT 151
15.6.2 PRODUCT PORTFOLIO 151
15.6.3 RECENT DEVELOPMENTS 151
15.7 EXSCIENTIA 152
15.7.1 COMPANY SNAPSHOT 152
15.7.2 REVENUE ANALYSIS 152
15.7.3 PRODUCT PORTFOLIO 153
15.7.4 RECENT DEVELOPMENTS 153
15.8 ARIA PHARMACEUTICALS, INC. 154
15.8.1 COMPANY SNAPSHOT 154
15.8.2 PRODUCT PORTFOLIO 154
15.8.3 RECENT DEVELOPMENTS 154
15.9 ATOMWISE INC. 156
15.9.1 COMPANY SNAPSHOT 156
15.9.2 PRODUCT PORTFOLIO 156
15.9.3 RECENT DEVELOPMENTS 156
15.10 BENEVOLENT AI 158
15.10.1 COMPANY SNAPSHOT 158
15.10.2 REVENUE ANALYSIS 158
15.10.3 PRODUCT PORTFOLIO 159
15.10.4 RECENT DEVELOPMENTS 159
15.11 BIOAGE INC., 160
15.11.1 COMPANY SNAPSHOT 160
15.11.2 PRODUCT PORTFOLIO 160
15.11.3 RECENT DEVELOPMENTS 160
15.12 CLOUD 161
15.12.1 COMPANY SNAPSHOT 161
15.12.2 PRODUCT PORTFOLIO 161
15.12.3 RECENT DEVELOPMENT 161
15.13 CYCLICA 162
15.13.1 COMPANY SNAPSHOT 162
15.13.2 PRODUCT PORTFOLIO 162
15.13.3 RECENT DEVELOPMENTS 162
15.14 DEEP GENOMICS 164
15.14.1 COMPANY SNAPSHOT 164
15.14.2 PRODUCT PORTFOLIO 164
15.14.3 RECENT DEVELOPMENTS 164
15.15 ENVISAGENICS 166
15.15.1 COMPANY SNAPSHOT 166
15.15.2 PRODUCT PORTFOLIO 166
15.15.3 RECENT DEVELOPMENTS 166
15.16 INSILICO MEDICINE 168
15.16.1 COMPANY SNAPSHOT 168
15.16.2 PRODUCT PORTFOLIO 168
15.16.3 RECENT DEVELOPMENTS 168
15.17 NUMEDII, INC. 170
15.17.1 COMPANY SNAPSHOT 170
15.17.2 PRODUCT PORTFOLIO 170
15.17.3 RECENT DEVELOPMENT 170
15.18 OWKIN INC. 171
15.18.1 COMPANY SNAPSHOT 171
15.18.2 PRODUCT PORTFOLIO 171
15.18.3 RECENT DEVELOPMENT 171
15.19 XTALPI INC. 172
15.19.1 COMPANY SNAPSHOT 172
15.19.2 PRODUCT PORTFOLIO 172
15.19.3 RECENT DEVELOPMENTS 172
16 QUESTIONNAIRE 174
17 RELATED REPORTS 177
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
